THERANEXUS announces its first half 2021 results

30/09/2021
Download PDF File (497Ko)

THERANEXUS and Beyond Batten Disease Foundation (BBDF) win US Investigational New Drug (IND) approval to start clinical development of BBDF 101

09/09/2021
Download PDF File (757Ko)

THERANEXUS publishes its cash position as of June 30 2021 and presents an update on the progress of its main programs

08/07/2021
Download PDF File (1546Ko)

Minutes of the combined general meeting of 16 June 2021

16/06/2021
Download PDF File (227Ko)

2020 full-year results and update on the progress of main programs

07/04/2021
Download PDF File (1443Ko)

THERANEXUS extends the capabilities of Neurolead, its active agent screening platform, to autophagy and neurological lysosomal storage disorders

09/03/2021
Download PDF File (326Ko)

Semi-annual liquidity contract summary - H2 2020

19/01/2021
Download PDF File (538Ko)

THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)